Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells

Linley, Adam J ORCID: 0000-0002-8176-5560, Karydis, Laura I, Mondru, Anil K, D'Avola, Annalisa, Al Shmrany, Humood, Cicconi, Silvia, Griffin, Rebecca, Forconi, Francesco, Pettitt, Andrew R, Kalakonda, Nagesh ORCID: 0000-0002-5300-1360
et al (show 7 more authors) (2021) Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. CLINICAL CANCER RESEARCH, 27 (20). pp. 5647-5659.

Access the full-text of this item by clicking on the Open Access link.


<h4>Purpose</h4>B-cell receptor (BCR) signaling is critical for the pathogenesis of chronic lymphocytic leukemia (CLL), promoting both malignant cell survival and disease progression. Although vital, understanding of the wider signaling network associated with malignant BCR stimulation is poor. This is relevant with respect to potential changes in response to therapy, particularly involving kinase inhibitors. In the current study, we describe a novel high-resolution approach to investigate BCR signaling in primary CLL cells and track the influence of therapy on signaling response.<h4>Experimental design</h4>A kinobead/mass spectrometry-based protocol was used to study BCR signaling in primary CLL cells. Longitudinal analysis of samples donated by clinical trial patients was used to investigate the impact of chemoimmunotherapy and ibrutinib on signaling following surface IgM engagement. Complementary Nanostring and immunoblotting analysis was used to verify our findings.<h4>Results</h4>Our protocol isolated a unique, patient-specific signature of over 30 kinases from BCR-stimulated CLL cells. This signature was associated with 13 distinct Kyoto Encyclopedia of Genes and Genomes pathways and showed significant change in cells from treatment-naïve patients compared with those from patients who had previously undergone therapy. This change was validated by longitudinal analysis of clinical trials samples where BCR-induced kinome responses in CLL cells altered between baseline and disease progression in patients failing chemoimmunotherapy and between baseline and treatment in patients taking ibrutinib.<h4>Conclusions</h4>These data comprise the first comprehensive proteomic investigation of the BCR signaling response within CLL cells and reveal unique evidence that these cells undergo adaptive reprogramming of this signaling in response to therapy.

Item Type: Article
Uncontrolled Keywords: B-Lymphocytes, Tumor Cells, Cultured, Humans, Protein Kinase Inhibitors, Cytological Techniques, Microspheres, Signal Transduction, Leukemia, Lymphocytic, Chronic, B-Cell
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 29 Sep 2021 13:15
Last Modified: 18 Jan 2023 21:27
DOI: 10.1158/1078-0432.CCR-21-0161
Open Access URL:
Related URLs: